tixagevimab and cilgavimab
Showing 1 - 22 of 22
Coronavirus Infections Trial in Moscow (tixagevimab/cilgavimab 150+150 mg, tixagevimab/cilgavimab 300+300 mg, regdanvimab)
Active, not recruiting
- Coronavirus Infections
- tixagevimab/cilgavimab 150+150 mg
- +2 more
-
Moscow, Russian FederationMoscow City Clinical Hospital 52
Aug 7, 2023
TIXAGEVIMAB/CILGAVIMAB Protection of Covid-19 in Transplanted
Withdrawn
- Solid Organ Transplant Recipients
- Blood and saliva samplings
-
Lyon, France
- +1 more
Aug 29, 2022
EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD
Completed
- COVID-19 Pandemic
- Transplant-Related Disorder
- tixagevimab-cilgavimab(AZD7442, AstraZeneca)
-
Roma, ItalyUniversità degli Studi di Roma Tor Vergata
Dec 17, 2022
A Non-interventional Multi-country Cohort Study to Assess Safety
Not yet recruiting
- Pregnancy
- +2 more
- (no location specified)
May 4, 2023
DoD Health System
Not yet recruiting
- COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease
- (no location specified)
Oct 4, 2022
Severe COVID-19 Infection in CLL or B-NHL Who Received
Not yet recruiting
- Chronic Lymphocytic Leukemia
- +2 more
- (no location specified)
Apr 6, 2023
Coronavirus Disease 2019 (COVID-19) Trial in United Kingdom, United States (AZD7442 (tixagevimab [AZD8895] + cilgavimab
Active, not recruiting
- Coronavirus Disease 2019 (COVID-19)
- AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
-
Birmingham, Alabama
- +15 more
Nov 7, 2022
COVID-19, Immunodeficiency Trial (Paxlovid 5 days, Paxlovid 10 days, Tixagevimab and Cilgavimab)
Not yet recruiting
- COVID-19
- Immunodeficiency
- Paxlovid 5 days
- +2 more
- (no location specified)
Oct 18, 2022
Chronic Lymphocytic Leukemia, COVID-19 Trial in Toronto (EVUSHELD)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- COVID-19
- EVUSHELD
-
Toronto, Ontario, CanadaSunnybrook Health Sciences Cente
Jul 18, 2022
SARS-CoV-2 Infection Trial in United States (Evusheld (tixagevimab+cilgavimab) IM or IV)
Recruiting
- SARS-CoV-2 Infection
- Evusheld (tixagevimab+cilgavimab) IM or IV
-
Fountain Valley, California
- +33 more
Jun 24, 2022
COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in
Not yet recruiting
- Follicular Lymphoma
- Cellular immunity vs SARS-CoV-2
- +6 more
-
Alessandria, IT, Italy
- +13 more
Oct 10, 2023
A Real-World Study of Anti-SARS-CoV-2 Monoclonal Antibodies
Recruiting
- Immunocompromised Patients
- Data collection
-
Paris, Ile De France, FranceAssistance Publique - Hôpitaux de Paris (AP-HP) - Cochin Hospita
Jul 5, 2022
COVID-19, SARS-CoV-2 Trial in Worldwide (AZD5156, Placebo, AZD7442 (EVUSHELD™))
Recruiting
- COVID-19, SARS-CoV-2
- AZD5156
- +2 more
-
Buenos Aires, Argentina
- +20 more
Jan 12, 2023
COVID-19 Trial in Worldwide (AZD7442, Placebo, Remdesivir)
Active, not recruiting
- COVID-19
- AZD7442
- +2 more
-
Tucson, Arizona
- +123 more
Mar 24, 2023
COVID-19 Trial in France, Germany, United Kingdom (COVID-19 convalescent and vaccinated plasma, Current standard of care)
Recruiting
- COVID-19
- COVID-19 convalescent and vaccinated plasma
- Current standard of care
-
Besançon, France
- +10 more
May 3, 2022
A Multi-Centre, Single-arm, Observational Study of EVUSHELD in
Active, not recruiting
- COVID-19
-
Qionghai, Hainan, China(2) Ruijin-Hainan Hospital Shanghai Jiaotong University School o
Jun 21, 2023
Coronavirus Disease 2019 (COVID-19), Healthy Volunteer Trial in Guangzhou, Shanghai (AZD7442 IM, Placebo IM, AZD7442 IV)
Active, not recruiting
- Coronavirus Disease 2019 (COVID-19)
- Healthy Volunteer
- AZD7442 IM
- +3 more
-
Guangzhou, China
- +1 more
Jul 27, 2022